Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Well, incidence numbers do look good - about the same as with GC4419 and Dusquetide, which I think are the two serious contenders. Brilacidin's delay of onset also seems to be similar to GC4419. I truly wish that Leo had released duration numbers. He didn't, sigh. Dusquetide had reduction from placebo 18 day to treatment 9 days. GC4419 median duration is probably what they say 1.5 to 2 days, maybe 3, but likely not more. These numbers are all medians calculated over ITT.

So, if brilacidin duration reduction (my guess) is 30 % or better we should be fine because Duesquetide has the problem of very low incident rate reduction (6 %), which may trip it's commercial changes.

It seems that IV drugs, for some reason have better duration numbers that oral. Even Kepivance scores medians of 4.5 and 5 days. But, then they have much higher risk of drug interaction (doing Kepivance in one indication revision at the time) than oral drugs. It is sort of wash - nice duration, if you can have it vs near certainty of no drug interactions but longer duration of SOM.

I guess there is room for both B and G.
BTW: check KMBJN:n post. There is a nice link to some earlier results with GC4419. That cleared me how GC4419 numbers are calculated. The article you found probably suffers from misunderstanding by the reporter.